Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov 2;24(1):1233.
doi: 10.1186/s12879-024-10151-3.

Effectiveness of pulse methylprednisolone in patients with non-human immunodeficiency virus pneumocystis pneumonia: a multicentre, retrospective registry-based cohort study

Yasuhiro Morimoto  1   2 , Hiroki Matsui  3   4 , Haruka Fujioka  1 , Yuya Homma  1 , Tatsuya Nagai  1 , Ayumu Otsuki  1 , Hiroyuki Ito  1 , Shin-Ichiro Ohmura  5 , Toshiaki Miyamoto  5 , Daisuke Shichi  6 , Tomohisa Watari  7 , Yoshihito Otsuka  7 , Kei Nakashima  8
Affiliations
Multicenter Study

Effectiveness of pulse methylprednisolone in patients with non-human immunodeficiency virus pneumocystis pneumonia: a multicentre, retrospective registry-based cohort study

Yasuhiro Morimoto et al. BMC Infect Dis. .

Abstract

Background: A recent database study and meta-analysis reported that adjunctive glucocorticoid therapy reduces mortality in patients with non-human immunodeficiency virus-associated (non-HIV) Pneumocystis jirovecii pneumonia (PCP), having hypoxemia. However, the optimal glucocorticoid dose remains unclear. Our study aimed to evaluate the effectiveness of pulse methylprednisolone compared with mild-to-moderate steroid doses in patients with non-HIV PCP.

Methods: This multicentre retrospective cohort study included adults with non-HIV PCP receiving adjunctive steroids at three Japanese tertiary care hospitals from June 2006 to March 2021. Patients were categorised into pulse methylprednisolone and mild-to-moderate dose groups. Pulse methylprednisolone involved an initial intravenous infusion of 500-1000 mg methylprednisolone daily, while the mild-to-moderate dose was lower. Primary and secondary outcomes were 30-day and 180-day mortality from treatment initiation. Patient characteristics were adjusted using propensity score analysis with overlap weighting. Subgroup analysis focused on patients with respiratory failure.

Results: The study included 139 patients with non-HIV PCP: 55 in the pulse methylprednisolone group and 84 in the mild-to-moderate dose group. After adjusting for patient background, 30-day mortality (14.2% vs. 15.5%, P = 0.850) and 180-day mortality (33.5% vs. 27.3%, P = 0.516) did not differ significantly between groups. Subgroup analysis revealed no significant associations among patients with respiratory failure.

Conclusions: After adjusting for patient characteristics, no difference in prognosis was observed between pulse methylprednisolone and mild-to-moderate dose groups in patients with non-HIV PCP. A mild-to-moderate dose of adjunctive corticosteroid may suffice for treating non-HIV PCP.

Keywords: Adjunctive corticosteroid treatment; Non-human immunodeficiency virus-infected patient; Pneumocystis pneumonia; Pulse methylprednisolone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart showing study design and patient selection PCP, Pneumocystis jirovecii pneumonia; HIV, human immunodeficiency virus
See this image and copyright information in PMC

References

    1. Thomas CF Jr, Limper AH. Pneumocystis Pneumonia. N Engl J Med. 2004;350:2487–98. - PubMed
    1. Tasaka S, Tokuda H. PneumocJiroveciiovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother. 2012;18:793–806. 10.1007/s10156-012-0453-0 - PubMed
    1. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002;34:1098–107. - PubMed
    1. Coyle PV, McCaughey C, Nager A, McKenna J, O’Neill H, Feeney SA, et al. Rising incidence of Pneumocystis Jirovecii pneumonia suggests iatrogenic exposure of immune-compromised patients may be becoming a significant problem. J Med Microbiol. 2012;61:1009–15. 10.1099/jmm.0.043984-0 - PubMed
    1. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96–128. 10.1164/rccm.2008-740ST - PubMed

Publication types

LinkOut - more resources